StockData

Absci vs 20/20 Biolabs

ABSI and AIDX side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABSI and AIDX compare

Absci is the larger company, worth 543 times as much as 20/20 Biolabs ($1.3B against $2.4M).

20/20 Biolabs grew revenue faster over the last twelve months (16.7% versus −62.3% for Absci).

20/20 Biolabs keeps more of each dollar of sales as profit, with a net margin of −183% compared with −7756% at Absci.

20/20 Biolabs scores higher on the StockData Score (6 against 5 for Absci), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABSIAIDX
Size and price
Market cap$1.3B$2.4M
Share price$7.47$0.185
Change, 1 year183%–
Change, 5 years−32.1%–
Beta (5Y)1.84–
Employees14014
StockData Score
Total score56 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S822×1.2× (better)
P/B5.2×1.5× (better)
FCF yield−8.5%–
Fair value–$0.593
Margin of safety–68.8%
Growth
Revenue growth (TTM)−62.3%16.7% (better)
Revenue growth, 5Y average−10.1%–
Profitability
Gross margin–29.6%
Operating margin−8085%−163% (better)
Net margin−7756%−183% (better)
FCF margin−6981%–
Return on equity−57.7% (better)−239%
Return on invested capital−122%–
Financial health
Debt / equity0.00–
Interest coverage−1342.5×−21.3× (better)
Current ratio10.63 (better)1.99
Altman Z-score29.50 (better)−8.93
Piotroski F-score35 (better)
Dividends and buybacks
Buyback yield−13.3%–
Shareholder yield−13.3%0.00% (better)
Ownership
Held by institutions88.3%4.2%
Held by insiders15.5%14.8%
Insider net buying, 12 months$801K–
Short interest, % of float24.7%0.52%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.